Pubertal Blockade and Hormone Therapy in Transgender Youth

NCT ID: NCT03557268

Last Updated: 2020-09-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 19 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-06-19
• Study Completion Date: 2020-09-09

Brief Summary

This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness, mitochondrial function and the microbiome.

Detailed Description

There will be a total of 6 study visits: baseline A, baseline B, 1 month after starting testosterone (visit A and B) and 12 months after starting testosterone (visit A and B). No medications will be administered as a part of this study.

Visit A procedures: Physical Examination, Laboratory, and Oral Glucose Tolerance Test (OGTT) visit.

This will be conducted at Childrens Hospital Colorado (CHCO) Clinical & Translational Research Centers (CTRC) facilities. Physical examination will include vital signs, anthropometric measurements, and breast/pubic hair staging as applicable (some subjects may have already undergone mastectomy/chest masculinizing surgery) by the PI. Subjects will fast for 8 hours prior to blood draw. Fasting blood work will be obtained, followed by an oral glucose load (75g glucola). Blood glucose and insulin concentrations will be drawn at baseline and 30, 60, 90 and 120 minutes after glucola administration. Serum will be obtained at baseline and 2 hours post-OGTT and used for bile acid and lipid metabolomic profile. The following questionnaires will be administered: REDCap Health Questionnaire, PedsQLTM 4.0 generic core questionnaire, PROMIS Pediatric Anxiety Short Form, PROMIS Pediatric Depressive Symptoms Short Form, Insomnia Severity Index, Morningness and Eveningness Scale. Participants will be mailed or emailed the 3-day dietary log prior to the visit and return it at this visit. They will be given a stool microbiome collection kit and urine collection kit to return at visit B. The medical chart will be reviewed for relevant health information and medications.

Part B: Vascular Imaging, MR-based imaging and spectroscopy, Exercise Capacity and Dual-energy X-ray (DXA) visit.

This will be conducted at the University of Colorado Denver Energy Balance Core and UCD Brain Imaging Center. The participant will be fasting for a minimum of 4 hours prior to the beginning of the study visit. The investigators will perform the tests in the following order:

1. Participants will return stool microbiome and urine collection kit.

2. Vascular imaging: carotid artery stiffness and intimal medial thickness and brachial artery flow-mediated dilation

3. Magnetic Resonance (MR) based imaging and spectroscopy

4. Oxygen consumption (VO2) peak exercise test on a stationary bicycle.

5. Total body dual energy x-ray absorptiometry (DXA)

6. Participants will be provided with an accelerometer and actigraphy watch to wear for a period of 7 days to measure level of habitual physical activity and sleep, respectively. They will also be provided a handout with instructions and a sleep and activity diary to be filled out each day during the 7 days of wear.

Conditions

Gender Identity; Gender Dysphoria; Gender Identity Disorder in Adolescence and Adulthood

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

On a GnRHa

Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue

No interventions assigned to this group

Not on GnRHa

Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Identify as female-to-male
• Age 13-16 years at the time of enrollment
• If on a gonadotropin-releasing hormone analogue, > 6 months exposure
• Plan to start testosterone clinically in < 6 months.

Exclusion Criteria

• Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
• Diabetes
• Antipsychotic medication
• Hypertension (resting BP ≥ 140/90 mm/Hg)
• Weight > 400 lbs (DXA and MRI limit)
• On estrogen and/or progesterone medications

• Minimum Eligible Age: 13 Years
• Maximum Eligible Age: 16 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Natalie J Nokoff, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Children's Hospital Colorado

Aurora, Colorado, United States

Countries

United States

Other Identifiers

17-2328

Identifier Type: -

Identifier Source: org_study_id